A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Healthy VolunteersPharmacologic Action

Interventions

DRUG

Group 1 AZD3293

AZD3293 oral solution

DRUG

Group 2 AZD3293

AZD3293 oral solution

DRUG

Group 3 AZD3293

AZD3293 oral solution

DRUG

Group 1 Itraconazole

itraconazole capsule

DRUG

Group 2 Diltiazem

Diltiazem ER tablet

DRUG

Group 3 Midazolam

midazolam syrup

Trial Locations (1)

Research Site, Cypress